Related Experiment Video
Updated: Mar 29, 2026
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
COnteMporary Modalities In Treatment of Heart Failure: a report from the COMMIT-HF registry
Mariusz Gąsior, Łukasz Pyka1, Jarosław Gorol
13rd Department of Cardiology, SMDZ in Zabrze, Medical University of Silesia, Katowice, Poland. wookash.p@gmail.com.
Insights
Heart failure (HF) is a global health issue. This study analyzed 1798 patients, finding that despite challenges, satisfactory long-term results are achievable with comprehensive care.
Area of Science:
- Cardiology
- Clinical Research
- Public Health
Background:
- Heart failure (HF) presents a significant global health challenge, contributing substantially to hospital admissions and carrying a poor prognosis.
- A high-volume cardiovascular center initiated the COMMIT-HF study to analyze clinical data, therapies, and outcomes in a large cohort of HF patients.
- Systolic HF, defined by left ventricular ejection fraction (LVEF) ≤ 35%, was the focus, excluding acute coronary syndromes.
Purpose of the Study:
- To analyze clinical data, administered therapies, and prognosis in a large cohort of patients with systolic heart failure.
- To provide valuable insights into the characteristics and outcomes of a complex HF patient population.
- To assess the feasibility of achieving satisfactory long-term results in HF management.
Main Methods:
- The COMMIT-HF study is a single-center observational study conducted at the Silesian Centre for Heart Diseases.
- The study enrolled 1798 adult HF patients with LVEF ≤ 35%, excluding those with acute coronary syndromes.
- Data collected included demographics, medical history, diagnostic and therapeutic hospitalisation data, and 12-month follow-up via national health-care provider records.
Main Results:
- The enrolled cohort (n=1798) had a mean age of 60.9 years, with 20.3% females and a mean LVEF of 26.06%.
- Common comorbidities included ischemic etiology (64.5%), atrial fibrillation (33.2%), diabetes mellitus (41.2%), and chronic kidney disease (29%).
- High rates of invasive procedures were observed, including ICD/CRT-D implantation (61.1%) and coronary angiography (56.2%). All-cause 12-month mortality was 12.5%, with a 28.9% HF-related rehospitalisation rate.
Conclusions:
- The COMMIT-HF study offers crucial data on a challenging heart failure patient population.
- Initial findings suggest that effective management strategies can lead to satisfactory long-term outcomes even in complex HF cases.
- The study underscores the importance of comprehensive diagnostics and therapy in improving HF patient prognosis.
Background And Aim:
Heart failure (HF) has become a global health problem and is a significant burden for health-care systems worldwide. It is reported as the reason for 1-4% of all hospital admissions in developed countries. The prognosis in HF remains unfavourable. Having at our disposal a large group of patients with systolic HF at a high-volume reference cardiovascular centre with the possibility to implement complete diagnostics and therapy we decided to analyse the clinical data, administered therapies, and prognosis in HF patients.
Methods:
The COMMIT-HF is a single-centre observational study that is underway in the Third Chair and Department of Cardiology of the Silesian Centre for Heart Diseases in Zabrze. The study population is a cohort of adult HF patients with left ventricular ejection fraction (LVEF) ≤ 35%. Patients with acute coronary syndromes are excluded from the analysis. Complete patient demographics: medical history, hospitalisation data (diagnostic and therapeutic), and in-hospital results are collected. Twelve-month follow-up is based on the information acquired from the national health-care provider.
Results:
As of 31 December 2013 a group of 1798 patients have been enrolled (mean age 60.9 ± 12.8 years, 20.3% of subjects female, mean LVEF 26.06 ± 6.09, ischaemic aetiology 64.5%, atrial fibrillation 33.2%, diabetes mellitus 41.2%, chronic kidney disease stage ≥ III 29%). A significant proportion of patients underwent invasive procedures (ICD/CRT-D implantation 61.1%, coronary angiography 56.2%, PCI 19.6%, CABG 5.1%, heart transplantation qualification 5.5%, IABP 2.5%). All-cause 12-month morality was 12.5%. HF-related rehospitalisation rate was 28.9%.
Conclusions:
The COMMIT-HF study will provide valuable information on the HF patient population. Initial analyses show that in this difficult patient population satisfactory long-term results can be achieved.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
08:24Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
Published on: May 25, 2020
Related Concept Videos
01:30Heart Failure V: Medical Management
01:22Heart Failure VI: Adjunct Therapies
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:29Cardiomyopathy V: Interprofessional Care
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:26Heart Failure III: Clinical Manifestations